IOVA

Iovance is a genuine commercial-stage story: Amtagvi (lifileucel) is the first approved one-time TIL cell therapy for advanced melanoma, and product revenue grew 60.6% to $264M in FY2025 off a near-zero base ($1.19M in FY2023, $164M in FY2024). That is real top-line momentum, not a clinical promise. But the financials show a company spending far more than it sells: operating income was -$403M on $264M of revenue (a -153% operating margin), net loss was -$391M, and operating cash flow was -$302M. The accumulated deficit is now -$2.78B. This is not a profitability-around-the-corner situation — losses have run between $342M and $444M every year since FY2021 with no narrowing trend.

The decisive fact is the cash runway. The company ended FY2025 with just $163M of cash against a $302M annual operating burn — well under a year of runway absent new financing. The 10-K's very first risk factor confirms it: 'We may need additional financing to fund our operations... Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights.' That dilution is already underway — shares outstanding jumped 25.6% YoY to 412M. An equity raise at these levels (price $4.21) is the base case, and it directly caps per-share upside for anyone buying today.